Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-08-15
2006-08-15
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S134100, C424S152100, C435S235100, C536S023100
Reexamination Certificate
active
07090845
ABSTRACT:
The present invention encompasses methods and compositions useful in diagnosing and treating hepatic disorders, especially those characterized by inflammation. The method comprises administration of an agent which prevents the interaction of MAdCAM with a MAdCAM binding partner or ligand. These compositions are useful in treating diseases or disorders involving α4β7/MAdCAM blockade, as well as inhibiting a primary event in the inflammatory response such as blocking interactions between intercellular adhesion molecules and their ligands. Disorders treatable using the methods disclosed herein include infections, especially viral infections, iatrogenic disorders, cholestatic disorders, hereditary disorders, sarcoidosis, organ transplant, and the like. The diagnostic methods of the invention can be employed to detect the presence of a disorder or to monitor the course of therapy used to treat the disorder.
REFERENCES:
patent: 5284931 (1994-02-01), Springer et al.
patent: 5962422 (1999-10-01), Nagy et al.
patent: 5968775 (1999-10-01), Houghton et al.
patent: 6020347 (2000-02-01), DeLaszlo et al.
patent: 6037324 (2000-03-01), Schwender et al.
patent: 6551593 (2003-04-01), Ringler et al.
patent: WO 96/24673 (1996-08-01), None
patent: WO 97/25351 (1997-07-01), None
Hu, K.Q. “up-regulation of intercellular adhesion molecule 1 transcription by hepatitis B virus X protein” Proc. Natl. Acad. Sci. (1992) vol. 89, pp. 11441-11445.
Lalor. P.F. “Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells” J. Immunol. (2002) vol. 169, No. 2, pp. 983-992.
Nolte. D. “Attenuation of Leukocyte Sequestration by Selective Blockade of PECAM-1 or VCAM-1 in Murine Endotoximia” Europ. Surg. Res. (2004) Vol. 36, pp. 331-337.
http://www.merck.com/mrkshared/mmanual/section4/chapter41/41a.jsp.
Grant, A.J. “MadCAM-1 Expressed in Chronic Inflammatory Liver Disease Supports Mucosal Lymphocyte Adhesion to Hepatic Endothelium” Hepatology (2001) 33, 5, 1065-1072.
Berlin et al., “α4 integrins mediate lymphocyte attachment and rolling under physiologic flow”Cell80(3) :413-422 (Feb. 10, 1995).
Berlin et al., “α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1”Cell74(1) :185-195 (Jul. 16, 1993).
Briskin et al., “Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue”American Journal of Pathology151(1) :97-110 (Jul. 1997).
Briskin et al., “MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1”Nature363(6428) :461-464 (Jun. 3, 1993).
Erle et al., “Complete amino acid sequence of an integrin β subunit (β7) identified in leukocytes”Journal of Biological Chemistry266(17) :11009-11016 (Jun. 15, 1991).
Gurish et al., “Expression of murine β7, α4, and β1integrin genes by rodent mast cells”Journal of Immunology149(6) :1964-1972 (Sep. 15, 1992).
Hanninen et al., “Vascular addressins are induced on islet vessels during insulitis in nonobese diabetic mice and are involved in lymphoid cell binding to islet endothelium”Journal of Clinical Investigation92(5) :2509-2515 (Nov. 1993).
Harrison's Priciple of Internal Medicine, 14 edition pp. 1736 (1998),
Hesterberg et al., “Rapid resolution of chronic colitis in the cottom-top tamarin with an antibody to a gut-homing integrin α4β7”Gastroenterology111(5) :1373-1380 (Nov. 1996).
Hillan et al., “Hepatic expression of the mucosal vascular addressin, MAdCAM-1, in hepatitis C”Modern Pathology(Abstract #956 from the Annual Meeting of the United States and Canadian Academy of Pathology held in San Francisco on Mar. 20-26, 1999) 12(1) :163A (Jan. 1999).
Jackson et al., “Potent α4β1 Peptide Antagonists as Anti-Inflammatory Agents”Journal of Medicinal Chemistry40(21) :3359-3368 (Oct. 10, 1997).
Kilger and Holzmann, “Molecular analysis of the physiological and pathophysiological role of α4-integrins”Journal of Molecular Medicine73(7) :347-354 (Jul. 1995).
Kilshaw and Murant, “Expression and regulation of β7(βp) integrins on mouse lymphocytes: relevance to the mucosal immune system”European Journal of Immunology21(10) :2591-2597 (Oct. 1991).
Kraal et al., “Expression of the mucosal vascular addressin, MAdCAM-1, on sinus-lining cells in the spleen”American Journal of Pathology147(3) :763-771 (Sep. 1995).
Kwan, M., “Examination of serum MAdCAM-1 levels in inflammatory bowel disease in an IL-10 receptor knockout model and its correlation to disease” (Abstract #73. Presented at the 10th Annual UC Davis Undergraduate Research Conference on Apr. 24, 1999).
Lazarovits et al., “Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen”Journal of Immunology133(4) :1857-1862 (Oct. 1984).
Madara et al., “Characterization of spontaneous colitis in cotton-top tamarins (Saguinus oedipus) and its response to sulfasalazine”Gastroenterology88(1 Pt 1) :13-19 (Jan. 1985).
Picarella et al., “Monoclonal antibodies specific for β7integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells”Journal of Immunology158(5) :2099-2106 (Mar. 1, 1997).
Podolsky et al., “Attenuation of colitis in the cotton-top tamarin by anti-α4 integrin monoclonal antibody”Journal of Clinical Investigation92(1) :372-380 (Jul. 1993).
Schweighoffer et al., “Selective expression of integrin α4β7 on a subset of human CD4+memory T cells with Hallmarks of gut-trophism”Journal of Immunology151(2) :717-729 (Jul. 15, 1993).
Shyjan et al., “Human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) demonstrates structural and functional similarities to the α4β7-integrin binding domains of murine MAdCAM-1, but extreme divergence of mucin-like sequences”Journal of Immunology156(8) :2851-2857 (Apr. 15, 1996).
Springer, T., “Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm”Cell76(2) :301-314 (Jan. 28, 1994).
Tanaka et al., “Inhibition of inflammatory liver injury by a monoclonal antibody against lymphocyte function-associated antigen-1”Journal of Immunology151 :5088-5095 (Nov. 1993).
Tidswell et al., “Structure-function analysis of the integrin β7subunit: identification of domains involved in adhesion to MAdCAM-1”Journal of Immunology159(3) :1497-1505 (Aug. 1, 1997).
Viney et al., “Mucosal addressin cell adhesion molecule-1: a structural and functional analysis demarcates the integrin binding motif”Journal of Immunology157(6) :2488-2497 (Sep. 15, 1996).
Walsh et al., “Integrin α4β7mediates human eosinophil interaction with MAdCAM-1, VCAM-1 and fibronectin”Immunology89(1) :112-119 (Sep. 1996).
The Leucocyte Antigen FactsBook, Barclay et al. pp. 298-299 (1997).
Stedman's Medical Dictionary, “www.pdrel.com/pdr/static.htm?path=pdrel/stedmans/c/s07941.htm,s07961.htm,s08043.htm,s31842.htm”, Wiliams & Wilkins (1995).
Fong Sherman
Hillan Kenneth J.
Brown Timothy
Genentech Inc.
Housel James
Merchant & Gould P.C.
LandOfFree
Diagnosis and treatment of hepatic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnosis and treatment of hepatic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosis and treatment of hepatic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3693186